Patel Minaxi H, Patel Rashmi D, Vanikar Aruna V, Kanodia Kamal V, Suthar Kamlesh S, Nigam Lovelesh K, Patel Himanshu V, Patel Ansy H, Kute Vivek B, Trivedi Hargovind L
a Department of Pathology, Laboratory Medicine, Transfusion Services and Immunohematology , IKDRC-ITS , Ahmedabad , India.
b Department of Nephrology and Clinical Transplantation , Institute of Kidney Diseases and Research Center, Dr H.L. Trivedi Institute of Transplantation Sciences (IKDRC-ITS) , Ahmedabad , India.
Ren Fail. 2017 Nov;39(1):294-298. doi: 10.1080/0886022X.2016.1268537.
Timely diagnosis of invasive fungal infections (IFI) in renal transplant (RT) patients on immunosuppression is often difficult, jeopardizing their life and graft. We reported IFI and their causative fungal agents in post-RT patients.
This was a retrospective 6-year clinical study carried out from 2010 to 2015 on 1900 RT patients. Clinical data included patient-donor demographics, time to onset of infection, risk factors and graft function in terms of serum creatinine (SCr). To identify IFI, we examined bronchoalveolar lavage (BAL), blood, tissue, and wound swab samples by conventional mycological methods.
IFI were diagnosed in 30 (1.56%) patients on triple immunosuppression, mainly males (n = 25) with mean age of 36.57 ± 11.9 years at 13.12 ± 18.35 months post-RT. Aspergillus species was identified in 11 BAL, one tissue, and one wound specimen each, 30.76% of these were fatal and 15.38% caused graft loss; Candida albicans was in nine BAL, four blood, two wound swab, and one tissue specimens, 25% of these were fatal and 25% had graft loss and one mucor in BAL which was fatal. Seven patients were diabetic, 10 had superadded cytomegalovirus infection, and 15 were anti-rejected.
IFI are associated with increased morbidity and mortality in RT patients. Triple immunosuppression, broad spectrum antibiotics for ≥ two weeks, diabetes and superadded infection are added risks for these patients. Prevention, early diagnosis, and appropriate management are necessary to improve their prognosis.
及时诊断接受免疫抑制治疗的肾移植(RT)患者的侵袭性真菌感染(IFI)往往很困难,这会危及他们的生命和移植肾。我们报告了RT术后患者的IFI及其致病真菌。
这是一项从2010年至2015年对1900例RT患者进行的回顾性6年临床研究。临床数据包括患者-供体人口统计学信息、感染发病时间、危险因素以及血清肌酐(SCr)方面的移植肾功能。为了识别IFI,我们通过传统真菌学方法检查支气管肺泡灌洗(BAL)、血液、组织和伤口拭子样本。
30例(1.56%)接受三联免疫抑制治疗的患者被诊断为IFI,主要为男性(n = 25),平均年龄36.57±11.9岁,在RT术后13.12±18.35个月发病。在11份BAL样本、1份组织样本和1份伤口标本中鉴定出曲霉菌种,其中30.76%的病例死亡,15.38%导致移植肾丢失;白色念珠菌存在于9份BAL样本、4份血液样本、2份伤口拭子样本和1份组织样本中,其中25%的病例死亡,25%出现移植肾丢失,1份BAL样本中发现毛霉菌,该病例死亡。7例患者患有糖尿病,10例合并巨细胞病毒感染,15例接受抗排斥治疗。
IFI与RT患者发病率和死亡率增加相关。三联免疫抑制、使用≥两周的广谱抗生素、糖尿病和合并感染是这些患者的额外风险因素。预防、早期诊断和适当管理对于改善他们的预后是必要的。